<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370603">
  <stage>Registered</stage>
  <submitdate>12/07/2016</submitdate>
  <approvaldate>15/07/2016</approvaldate>
  <actrnumber>ACTRN12616000941460</actrnumber>
  <trial_identification>
    <studytitle>A randomised control trial of mild opioids versus strong opioids for post-discharge analgesia following orthopaedic fracture surgery</studytitle>
    <scientifictitle>A randomised control trial of oxycodone hydrochloride versus paracetamol with codeine for post-discharge analgesia following orthopaedic fracture surgery</scientifictitle>
    <utrn>U1111-1183-7247</utrn>
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Pain</healthcondition>
    <healthcondition>Fracture</healthcondition>
    <healthcondition>Orthopaedic Surgery</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Fractures</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Anaesthesiology</conditioncode1>
      <conditioncode2>Pain management</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Paracetamol 500mg and Codeine phosphate 8mg
1-2 oral tablets, 4 times per day for 2 weeks (Maximum allowed 8 tablets in 24hrs) followed by dose reduction to cessation during week 3. 
Total number of tablets taken (1 or 2) will be determined by patient during days 1 -14.
Adherence will be monitored via patient self-report during trial period then tablet return on study completion. </interventions>
    <comparator>Oxycodone Hydrochloride 5mg 
1-2 oral tablets, 4 times per day for 2 weeks (Maximum allowed 8 tablets in 24hrs) followed by dose reduction to cessation during week 3. 
Total number of tablets taken (1 or 2) will be determined by patient pain during days 1 -14..
Adherence will be monitored via patient self-report during trial period then tablet return on study completion. </comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Pain (Numeric Pain Rating Scale (NRS-11)) </outcome>
      <timepoint>Average of first 7 days of treatment. (Day 1, 2, 3, 4, 5, 6 &amp; 7)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life (EQ-5D-5L)
</outcome>
      <timepoint>Baseline, Day 3, 7, 14 &amp; 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mobility (Question 1 of EQ-5D-5L)</outcome>
      <timepoint>Baseline, Days 3,  7, 14, 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain (The Numeric Pain Rating scale)</outcome>
      <timepoint>Collected Daily, average of Days 8-21 of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Treatment Adverse events 
(Self report, Yes or No to common known adverse reactions) (Constipation, Drowsiness, Nausea, Vomiting, Hallucinations, Dizziness, Confusion and Skin rash)</outcome>
      <timepoint>Collected daily, Days 1-21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Global perceived effect (Likert scale; -5 (vastly worse) to 0 (unchanged), to +5 (completely recovered)..
</outcome>
      <timepoint>Days 3, 7, 14 &amp; 21</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Return to work (Yes or No, subject self-report)</outcome>
      <timepoint>Day 21</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Orthopaedic fracture of a long bone (humerus, radius, ulna, femur, tibia or fibula) or the pelvis, patella, calcaneus or talus requiring surgical fixation.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>- Pathological fractures
- Multi-system trauma injuries (major head, chest or abdominal injuries)
- Major infection following surgery
- Opioid dependency</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2016</anticipatedstartdate>
    <actualstartdate>27/07/2016</actualstartdate>
    <anticipatedenddate>31/07/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>116</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>21/08/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Liverpool Hospital - Liverpool</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Ian Harris</primarysponsorname>
    <primarysponsoraddress>Liverpool Hospital
Orthopaedic Department
Locked Bag 7103
Liverpool BC NSW 1871</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>State Insurance Regulatory Authority</fundingname>
      <fundingaddress>Level 25, 580 George Street
Sydney NSW 2000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Opioid analgesics (morphine-like pain killers) are the drug of choice for post-operative pain fracture management. Previous research has been found that most, if not all, surgically managed fracture patients are discharge home from hospital with strong opioids (largely Panadiene Forte, Endone and Oxycontin). Despite the overwhelming push for effective postoperative pain control, at present there is no clear consensus on which pain medication is best for pain management after discharge home from hospital following an orthopaedic fracture. We aim to determine whether over the counter paracetamol plus codeine provides adequate pain relief compared to stronger oxycodone based pain killers. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter new england human research ethics committee</ethicname>
      <ethicaddress>Hunter New England Local Health District
Locked Bag 1
New Lambton NSW 2305</ethicaddress>
      <ethicapprovaldate>16/07/2015</ethicapprovaldate>
      <hrec>HREC/15/HNE/158</hrec>
      <ethicsubmitdate>30/04/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Ian Harris</name>
      <address>Orthopaedic Department
Liverpool Hospital 
Locked Bag 7103
Liverpool BC NSW 1871</address>
      <phone>+61 2 8738 9254</phone>
      <fax />
      <email>iaharris1@gmail.com</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Deanne Jenkin</name>
      <address>Ingham Institute of Applied Medical Research
1 Campbell street
Liverpool NSW 2170</address>
      <phone>+61 2 8738 9254</phone>
      <fax />
      <email>deanne.jenkin@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Deanne Jenkin</name>
      <address>Ingham Institute of Applied Medical Research
1 Campbell street
Liverpool NSW 2170</address>
      <phone>+61 2 8738 9254</phone>
      <fax />
      <email>deanne.jenkin@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Deanne Jenkin</name>
      <address>Ingham Institute of Applied Medical Research
1 Campbell street
Liverpool NSW 2170</address>
      <phone>+61 2 8738 9254</phone>
      <fax />
      <email>deanne.jenkin@sswahs.nsw.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>